Arrowhead Research | ARWR - Interest Expense On Debt


Arrowhead Research reported $22.5M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 304M 23M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
TG Therapeutics USD 6.53M 187K Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.35M 311K Dec/2025